Literature DB >> 9616362

Low antigen dose favours selection of somatic mutants with hallmarks of antibody affinity maturation.

A González-Fernández1, C Milstein.   

Abstract

The immunization schedule is critical for the derivation of high-affinity antibodies, low antigen dose being particularly favourable for the development of a more efficient memory response. To analyse the molecular events underpinning this preference, we analysed the early maturation of the response to the hapten 2-phenyloxazolone (phOx) using low and high doses of immunogen. The phOx response is initially dominated by antibodies expressing the VkOx1-Jk5 light chain and the hallmark of the early stages of maturation is the substitution of His 34 by Asn or Gln increasing affinity 10- or eightfold, respectively, and of Tyr 36 by Phe. High-affinity antibodies express mutations at both sites. We cloned and sequenced VkOx1-Jk5 light chains from antigen-specific B cells taken 14 and 21 days after immunization with high and low antigen doses. We found that overall, the derived sequences were more mutated both at longer times and at higher dose. At day 14, His 34 was more frequently mutated at the higher than at the lower dose, while at day 21 the reverse was true. On the other hand, the His 34/Tyr 36 mutation pair was more frequent at low than high doses at both 14 and 21 days. Furthermore, at both times, the low immunization protocol yielded double mutants in cells with a lower mutation background. It appears therefore that while the higher dose may favour the acquisition of individual critical mutations, low-dose immunization favours the selection of a more focused mutational pattern, whereby advantageous mutations are associated with a low mutational background.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9616362      PMCID: PMC1364172          DOI: 10.1046/j.1365-2567.1998.00423.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  22 in total

1.  Antigen-induced B-cell death and elimination during germinal-centre immune responses.

Authors:  K M Shokat; C C Goodnow
Journal:  Nature       Date:  1995-05-25       Impact factor: 49.962

2.  Passenger transgenes reveal intrinsic specificity of the antibody hypermutation mechanism: clustering, polarity, and specific hot spots.

Authors:  A G Betz; C Rada; R Pannell; C Milstein; M S Neuberger
Journal:  Proc Natl Acad Sci U S A       Date:  1993-03-15       Impact factor: 11.205

Review 3.  Cyclic re-entry of germinal center B cells and the efficiency of affinity maturation.

Authors:  T B Kepler; A S Perelson
Journal:  Immunol Today       Date:  1993-08

Review 4.  Discriminating intrinsic and antigen-selected mutational hotspots in immunoglobulin V genes.

Authors:  A G Betz; M S Neuberger; C Milstein
Journal:  Immunol Today       Date:  1993-08

Review 5.  Germinal centers.

Authors:  I C MacLennan
Journal:  Annu Rev Immunol       Date:  1994       Impact factor: 28.527

6.  The effect of carrier and carrier priming on the kinetics and pattern of somatic mutation in the V chi Ox1 gene.

Authors:  E Källberg; D Gray; T Leanderson
Journal:  Eur J Immunol       Date:  1995-08       Impact factor: 5.532

7.  Analysis of somatic hypermutation in mouse Peyer's patches using immunoglobulin kappa light-chain transgenes.

Authors:  A González-Fernández; C Milstein
Journal:  Proc Natl Acad Sci U S A       Date:  1993-11-01       Impact factor: 11.205

8.  Development of antibody diversity in single germinal centers: selective expansion of high-affinity variants.

Authors:  M Ziegner; G Steinhauser; C Berek
Journal:  Eur J Immunol       Date:  1994-10       Impact factor: 5.532

9.  Direct evidence that human follicular dendritic cells (FDC) rescue germinal centre B cells from death by apoptosis.

Authors:  E Lindhout; M L Mevissen; J Kwekkeboom; J M Tager; C de Groot
Journal:  Clin Exp Immunol       Date:  1993-02       Impact factor: 4.330

10.  Tracing B cell development in human germinal centres by molecular analysis of single cells picked from histological sections.

Authors:  R Küppers; M Zhao; M L Hansmann; K Rajewsky
Journal:  EMBO J       Date:  1993-12-15       Impact factor: 11.598

View more
  13 in total

1.  Problems in using statistical analysis of replacement and silent mutations in antibody genes for determining antigen-driven affinity selection.

Authors:  Biplab Bose; Subrata Sinha
Journal:  Immunology       Date:  2005-10       Impact factor: 7.397

2.  Correlation of molecular characteristics, isotype, and in vitro functional activity of human antipneumococcal monoclonal antibodies.

Authors:  H E Baxendale; D Goldblatt
Journal:  Infect Immun       Date:  2006-02       Impact factor: 3.441

3.  Heterologous HA DNA vaccine prime--inactivated influenza vaccine boost is more effective than using DNA or inactivated vaccine alone in eliciting antibody responses against H1 or H3 serotype influenza viruses.

Authors:  Shixia Wang; Chris Parker; Jessica Taaffe; Alicia Solórzano; Adolfo García-Sastre; Shan Lu
Journal:  Vaccine       Date:  2008-05-19       Impact factor: 3.641

4.  Apobec3 encodes Rfv3, a gene influencing neutralizing antibody control of retrovirus infection.

Authors:  Mario L Santiago; Mauricio Montano; Robert Benitez; Ronald J Messer; Wes Yonemoto; Bruce Chesebro; Kim J Hasenkrug; Warner C Greene
Journal:  Science       Date:  2008-09-05       Impact factor: 47.728

5.  Antibody avidity, persistence, and response to antigen recall: comparison of vaccine adjuvants.

Authors:  Sonia Budroni; Francesca Buricchi; Andrea Cavallone; Patricia Bourguignon; Magalie Caubet; Vincent Dewar; Ugo D'Oro; Oretta Finco; Nathalie Garçon; Mohamed El Idrissi; Michel Janssens; Geert Leroux-Roels; Arnaud Marchant; Tino Schwarz; Pierre Van Damme; Gianfranco Volpini; Robbert van der Most; Arnaud M Didierlaurent; Wivine Burny
Journal:  NPJ Vaccines       Date:  2021-05-21       Impact factor: 7.344

Review 6.  Novel viral vectored vaccines for the prevention of influenza.

Authors:  Teresa Lambe
Journal:  Mol Med       Date:  2012-10-24       Impact factor: 6.354

7.  Superior neutralizing antibody response and protection in mice vaccinated with heterologous DNA prime and virus like particle boost against HPAI H5N1 virus.

Authors:  Heng Ding; Cheguo Tsai; Ramona Alikiiteaga Gutiérrez; Fan Zhou; Philippe Buchy; Vincent Deubel; Paul Zhou
Journal:  PLoS One       Date:  2011-01-28       Impact factor: 3.240

8.  IgVH genes from different anatomical regions, with different histopathological patterns, of a rheumatoid arthritis patient suggest cyclic re-entry of mature synovial B-cells in the hypermutation process.

Authors:  M M Souto-Carneiro; V Krenn; R Hermann; A König; H K Müller-Hermelink
Journal:  Arthritis Res       Date:  2000-05-19

9.  Pre-clinical antigenicity studies of an innovative multivalent vaccine for human visceral leishmaniasis.

Authors:  Pedro Cecílio; Begoña Pérez-Cabezas; Laura Fernández; Javier Moreno; Eugenia Carrillo; José M Requena; Epifanio Fichera; Steven G Reed; Rhea N Coler; Shaden Kamhawi; Fabiano Oliveira; Jesus G Valenzuela; Luigi Gradoni; Reinhard Glueck; Gaurav Gupta; Anabela Cordeiro-da-Silva
Journal:  PLoS Negl Trop Dis       Date:  2017-11-27

10.  Sequential Immunization Elicits Broadly Neutralizing Anti-HIV-1 Antibodies in Ig Knockin Mice.

Authors:  Amelia Escolano; Jon M Steichen; Pia Dosenovic; Daniel W Kulp; Jovana Golijanin; Devin Sok; Natalia T Freund; Alexander D Gitlin; Thiago Oliveira; Tatsuya Araki; Sarina Lowe; Spencer T Chen; Jennifer Heinemann; Kai-Hui Yao; Erik Georgeson; Karen L Saye-Francisco; Anna Gazumyan; Yumiko Adachi; Michael Kubitz; Dennis R Burton; William R Schief; Michel C Nussenzweig
Journal:  Cell       Date:  2016-09-08       Impact factor: 41.582

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.